Adagio Medical Holdings, Inc.

Health Care
Medical/Dental Instruments

Safety Score

Market Cap $33.74M
PE 3
Debt $13.75M
Cash $28.26M
EV $19.23M
FCF -$4.42M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$10.30M
EBIT	$11.98M
ROE	13%
ROA	11%
FCF	-$4.42M
Equity	$76.56M
Growth Stability	1
PE	3.28
PB	0.44
P/FCF	-7.63
P/S	138.84
Price/Cash	0.84
Debt/Equity	0.18
Debt/FCF	-3.11
Net Margins	3K%
Gross Margins	-239%
Op. Margins	5K%

Earnings Growth QoQ	-119%
Market Cap	$33.74M
Revenue	$243.00K
Assets	$107.20M
Total Debt	$13.75M
Cash	$28.26M
Shares Outstanding	14.06M
EV	19.23M
Safety Score	67%
Working Capital	27.11M
Current Ratio	4.42
Gross Profit	-$580.00K
Shares Growth 3y	10%
Equity Growth QoQ	-152%
Equity Growth YoY	-162%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Adagio Medical, Inc., is a medical device company located in Laguna Hills, California. Co-founded in 2011 by Dr. James Cox, the inventor of gold standard Cox-Maze procedure, and Olav Bergheim, a serial entrepreneur, Adagio Medical is developing innovative ablation technologies for the treatment of cardiac arrhythmias including atrial fibrillation, atrial flutter, and ventricular tachycardia. Adagios unique portfolio is based on Ultra-Low Temperature Cryoablation (ULTC) and Pulsed-Field Cryoablation (PFCA) designed to produce durable, contiguous, transmural lesions anywhere in the heart.

SEC Filings

Direct access to Adagio Medical Holdings, Inc. (ADGM) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30

Sector Comparison

How does Adagio Medical Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Adagio Medical Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Adagio Medical Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Adagio Medical Holdings, Inc..

Years

Calculation mode

= -$44M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$4.4M	-$4.4M	-$4.4M	-$4.4M	-$4.4M	-$4.4M	-$4.4M	-$4.4M	-$4.4M	-$4.4M	-$4.4M	-$44M
DCF		-$4M	-$3.7M	-$3.3M	-$3M	-$2.7M	-$2.5M	-$2.3M	-$2.1M	-$1.9M	-$1.7M	-$17M
Value	-$44M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	07/2023	TTM
Net Margins	-	3K%
ROA	-	11%
ROE	-	13%

Good Net Margins (2.73K%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	07/2023	TTM
Debt over FCF	-	-3.11
Debt over Equity	-	0.18
Growth Stability	-	1

Good Debt/FCF ratio (-3.11)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.18)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	07/2023	CAGR 5Y
Revenue YoY growth	-	-
Earnings YoY growth	-	-
Equity YoY growth	-	-
FCF YoY growth	-	-